CEO Today Healthcare Awards

www.ceotodaymagazine.com CEO Today Healthcare Awards 2019 43 UNITED KINGDOM FIRM PROFILE Our strategy is to use science-based innovation to deliver better patient outcomes. We aim to lead in growing areas of healthcare The Novartis Group We are Novartis, and we are reimagining medicine. Novartis focuses on innovative medicines as well as generics and biosimilars. We are a leading global medicines company powered by data and digital. We harness the power of science to push boundaries, develop breakthrough treatments and deliver them directly to the millions of people in the UK who need them. At Novartis we are reimagining medicine in terms of how we fight disease, deliver treatments to patients and operate as a company. Today, we are working on exciting new innovations that, just a few years ago, were the stuff of science fiction. Haseeb Ahmad. Managing Director, UK, Ireland and Nordics of Novartis Pharmaceuticals & Country President UK Innovative Medicines Our specialist business units, Novartis Oncology and Novartis Pharmaceuticals, form our Innovative Medicines Division. Novartis Oncology is dedicated to revolutionising the development of innovative medicines for a variety of cancers and rare diseases. Novartis Pharmaceuticals focuses on the delivery of innovative treatments in the areas of cardiovascular, respiratory, neuroscience, ophthalmology, immunology, hepatology and dermatology. Generics and Biosimilars Sandoz is a global leader in generic medicines and biosimilars. It is committed to driving access to high-quality medicines around the world. In the UK, Sandoz has a long history of providing affordable products to the NHS. Our Mission At Novartis, our mission is to discover new ways to improve and extend people’s lives. Discovering new treatments requires imagination and visionary thinking combined with determination and rigour. This happens every day at Novartis. We are proud of our contribution to medical progress, but there’s still a long way to go. Through the discovery, research and development of innovative treatments and technologies, we aim to tackle devastating diseases and help people in the UK and around the world live longer, better lives. HASEEB AHMAD CEO of Novartis UK ABOUT HASEEB AHMAD Mr Ahmad joins Novartis UK from Merck Sharp & Dohme (MSD) where he wasManagingDirector for MSD Greece, Cyprus and Malta. He brings almost 20 years of experience in the industry at a multi- country and global level, including more than 13 years based in the UK. www.novartis.co.uk